v3.25.4
ALLIANCES - Financial Information Pertaining to Alliances (Pfizer) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Alliance Statement [Line Items]      
Total Revenues $ 48,194 $ 48,300 $ 45,006
Cost of products sold – profit sharing [1] 13,936 13,968 10,693
Other (income)/expense, net 674 893 (1,158)
Receivables 11,414 10,747  
Accounts payable 3,575 3,602  
Net product sales      
Alliance Statement [Line Items]      
Total Revenues 46,756 46,778 43,778
Eliquis      
Alliance Statement [Line Items]      
Total Revenues 14,443 13,333 12,206
Pfizer      
Alliance Statement [Line Items]      
Total Revenues 14,443 13,333 12,206
Alliance revenues      
Alliance Statement [Line Items]      
Total Revenues 15,035 14,066 13,151
Cost of products sold – profit sharing 7,181 6,597 6,067
Other (income)/expense, net (23) (137) (49)
Receivables 198 221  
Accounts payable 1,684 1,578  
Deferred income 175 222  
Alliance revenues | Net product sales      
Alliance Statement [Line Items]      
Total Revenues 14,588 13,587 12,543
Alliance revenues | Pfizer      
Alliance Statement [Line Items]      
Total Revenues 115 146 200
Cost of products sold – profit sharing 6,980 6,419 5,833
Other (income)/expense, net (42) (42) (42)
Receivables 176 189  
Accounts payable 1,599 1,463  
Deferred income 95 137  
Alliance revenues | Pfizer | Net product sales      
Alliance Statement [Line Items]      
Total Revenues $ 14,328 $ 13,187 $ 12,006
Alliance revenues | Pfizer | Eliquis | Minimum      
Alliance Statement [Line Items]      
Percentage of reimbursement for development costs from alliance partner 50.00%    
Alliance revenues | Pfizer | Eliquis | Maximum      
Alliance Statement [Line Items]      
Percentage of reimbursement for development costs from alliance partner 60.00%    
[1] Excludes amortization of acquired intangible assets.